Lipid Supplements for Mitochondrial Dysfunction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nutritional supplements fail to effectively address mitochondrial dysfunction and cell membrane damage, leading to various health issues such as chronic degenerative disorders, autoimmune diseases, and aging-related symptoms, as they do not provide the specific phospholipid ratios found in mitochondrial membranes.
Innovation Solution
Development of new lipid formulations and Cyanithin compositions enriched with specific phospholipids like phosphatidylglycerol, phosphatidylcholine, and phosphatidylethanolamine, derived from plant and microbial sources, which are tailored to match the fatty acid profiles of mitochondrial membranes, combined with antioxidants and probiotics to enhance bioavailability and cellular energy production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nutritional supplements are used, then general nutrition is provided, but mitochondrial dysfunction and cell membrane damage are not effectively addressed due to lack of specific phospholipid ratios
Solution Approach 1:
The patent applies local quality by providing organ-specific phospholipid formulations tailored to the unique phospholipid composition requirements of different mitochondrial membranes. Each organ (heart, brain, liver, kidney, lung, muscle) receives a customized phospholipid profile matching its specific mitochondrial membrane composition, rather than a generic supplement formulation. This resolves the contradiction by making the supplement adaptable to specific mitochondrial needs while maintaining high reliability for addressing mitochondrial dysfunction.
Solution Approach 2:
The patent changes the parameter of phospholipid composition ratios to match specific mitochondrial membrane profiles. By adjusting the concentrations and types of phospholipids (phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, cardiolipin, phosphatidylglycerol) in the supplement formulation, the patent creates tailored compositions for different organs and disease states, thereby achieving both reliability in treating mitochondrial dysfunction and adaptability to specific physiological requirements.
2Reliability
If lipid replacement therapy is implemented with specific phospholipid formulations, then mitochondrial function is restored and energy production improves, but the complexity of formulation development and production increases
Solution Approach 1:
The patent applies universality by developing a platform technology for lipid replacement therapy that can be adapted across multiple organs and disease states. The core formulation methodology and production processes are universal, while only the specific phospholipid ratios need adjustment for different applications. This reduces formulation and production complexity while maintaining the ability to restore mitochondrial function across various tissues and conditions.
Solution Approach 2:
The patent segments the complex task of mitochondrial support into specific phospholipid components (phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, cardiolipin, phosphatidylglycerol) that can be independently sourced, formulated, and optimized. This segmentation allows for more manageable production processes while achieving the comprehensive effect of restoring mitochondrial function through targeted supplementation.
3Productivity
If enriched phospholipid compositions are used to match mitochondrial membranes, then cellular energy production is enhanced and fatigue is reduced, but the cost of sourcing and purifying specific lipid components increases
Solution Approach 1:
The patent applies extraction by isolating and purifying specific phospholipid components from natural sources to create concentrated formulations. By extracting only the essential phospholipids needed for mitochondrial function (phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, cardiolipin, phosphatidylglycerol) and removing unnecessary components, the patent achieves high cellular energy production with cost-effective dosing, as only the active ingredients are supplied in therapeutic amounts.
Data Source
AI summary
Nutritional supplement formulations suitable for specific enhancement of cell and mitochondrial function comprise enriched formulations of phospholipids and chemical precursors containing specifically identified concentrations of phosphatidylglycerol, phosphatidic acid and phosphatidylcholine, and mitochondrial and cell membrane phospholipid molecules as well as other desirable constituents. Methods of enriching extracted sources of cell and mitochondrial membrane molecules and precursors from microbes, plants and other sources are also set forth. The formulae can be combined with nutritional, prebiotic, and probiotic (microbial) factors that increase bioavailability through the digestive tract and increase absorption at the cellular and subcellular levels. These lipid combinations can be used to treat mitochondrial disorders associated with medical pathologies, chronic illnesses and syndromes, or to maintain lipid balance for normal mitochondrial function, and can be administered in many different forms. The various combinations specifically enriched in the correct phospholipid and correct fatty acid residues can be used to treat organ, tissue, cell or system.